Carisma Therapeutics, Inc. (CARM)

Carisma Therapeutics' stock has been impacted by several events in the past six months. The stock plummeted after receiving a Nasdaq delisting determination in October 2025 and plans to transfer to the OTCID market. Carisma announced its delisting from Nasdaq and SEC deregistration in December 2025. Several analysts downgraded Carisma Therapeutics in December 2024 due to a lack of near-term catalysts and a strategic refocus. A restructuring announcement in June 2025, involving discontinuing the CT-0525 program and a 34% workforce reduction, initially led to a surge but the stock remained down year-to-date. Carisma Therapeutics has beaten consensus EPS estimates three times over the last four quarters.

As a clinical-stage biopharmaceutical company focused on research and development, Carisma Therapeutics, Inc. does not currently have any commercially available products or services, and therefore, there is no discernible demand seasonality.

Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for serious diseases, particularly cancer and liver fibrosis. The company utilizes its CAR-M platform to engineer macrophages and monocytes to target tumor-associated antigens. Its pipeline includes CT-2401 for liver fibrosis, CT-1119 in Phase I trials for advanced solid tumors, an anti-GPC3 in vivo CAR-M therapy with Moderna for hepatocellular carcinoma, CT-0508 for solid tumors overexpressing HER2, and CT-0525, which was discontinued as part of a restructuring.

Carisma Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States, with a primary focus on developing therapies within the United States.

Carisma Therapeutics' brand reputation has been negatively impacted by challenging corporate developments. The Nasdaq delisting and transfer to the OTCID market, along with the announcement of an orderly wind-down and the unlikelihood of cash distribution, have likely damaged investor confidence. The strategic restructuring, including discontinuing CT-0525 and a 34% workforce reduction, indicates significant operational challenges. Analyst downgrades also reflect negative sentiment regarding the company's near-term prospects.

As of October 10, 2025, Carisma Therapeutics, Inc. has 30 institutional owners and shareholders holding a total of 2,710,352 shares. Major institutional shareholders include Merck & Co., Inc., Vanguard Extended Market Index Fund Investor Shares (VEXMX), BlackRock, Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, State Street Corp, Northern Trust Corp, Gts Securities Llc, BSVO - EA Bridgeway Omni Small-Cap Value ETF, Bridgeway Capital Management Inc., Moderna, Inc. (12.09% of shares), AbbVie, Inc. (4.44% of shares), and University of Pennsylvania (Investment) (2.992% of shares). Individual investors hold approximately 10.82% of the company's stock, with Michael Klichinsky owning the most shares among individuals.